CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Columbus, Ohio, United States and 47 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Columbus, Ohio, United States and 23 other locations
in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...
Phase 1, Phase 2
Columbus, Ohio, United States and 33 other locations
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (C...
Phase 1, Phase 2
Columbus, Ohio, United States and 11 other locations
chemotherapy in induction-eligible patients with acute myeloid leukemia.This study involves the following:* Venetoclax and azacitidine (inve...
Phase 2
Columbus, Ohio, United States and 8 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Columbus, Ohio, United States and 110 other locations
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes l...
Phase 1, Phase 2
Columbus, Ohio, United States and 18 other locations
with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...
Phase 3
Columbus, Ohio, United States and 125 other locations
in treating patients with T-cell large granular lymphocytic leukemia that has come back (relapsed) or has not responded to previous treatmen...
Phase 1, Phase 2
Columbus, Ohio, United States
This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia...
Phase 1
Columbus, Ohio, United States and 2 other locations
Clinical trials
Research sites
Resources
Legal